



News Release

Suven Life Sciences Secures Two Product Patents from European Patent Office (EPO) for the treatment of Neurodegenerative diseases.

HYDERABAD, INDIA (November 27th, 2007) – Suven Life Sciences Ltd (Suven) announces today that the European Patent Office (EPO) granted Two Patents, 1523486 and 1581538 to Suven and are valid until June 2022. The granted claims of the patent include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like, Alzheimer's, Attention deficient hyperactivity, Huntington's disease, Parkinson & Schizophrenia

Suven has three (3) European Patents granted until now and all of them have been validated in all the 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland. There are several patent applications from Suven Discovery Research are in the pipeline that have completed the administrative and technical diligence from the patent offices from major countries and would be granted shortly.

Suven has already filed its first Investigational New Drug (IND) application with DCGI to conduct the clinical Phase-I study on their developmental candidate SUVN-502 and several candidates are in discovery pipeline undergoing GLP pre-clinical studies.

We continue to work on G-Protein coupled receptor (GPCR) targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential, says Venkat Jasti, CEO of Suven.

Suven Life Sciences is a Hyderabad based Life Science Company, a **Collaborative Research Partner (CRP)** since 2006 in Drug Discovery for global Pharma major and is a pioneer in **Contract Research and Manufacturing Services (CRAMS)** since 1995 and **Drug Discovery and Development Support Services (DDDSS)** since 2005. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade.

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;